Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $1,380,150.00 in Stock

05 Oct 2026, 04:08 by Teresa Graham · The Cerbat Gem

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $92.01, for a total value of $1,380,150.00. Following the sale, the chief executive officer owned 537,540 shares in the company, valued at $49,459,055.40. The trade was a 2.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cameron Turtle also recently made the following trade(s):

On Tuesday, September 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $87.29, for a total value of $1,309,350.00.
On Monday, August 3rd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $95.51, for a total value of $1,432,650.00.

Spyre Therapeutics Price Performance

NASDAQ:SYRE opened at $93.19 on Monday. Spyre Therapeutics, Inc. has a twelve month low of $15.86 and a twelve month high of $110.18. The firm has a market capitalization of $8.20 billion, a price-to-earnings ratio of -47.79 and a beta of 3.10. The stock’s 50 day moving average price is $95.71 and its two-hundred day moving average price is $81.70.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.40. As a group, analysts anticipate that Spyre Therapeutics, Inc. will post -2.71 earnings per share for the current year.

Institutional Trading of Spyre Therapeutics

Several hedge funds have recently added to or reduced their stakes in SYRE. GAMMA Investing LLC grew its holdings in Spyre Therapeutics by 26.8% in the 2nd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $59,000 after buying an additional 140 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Spyre Therapeutics during the second quarter worth $31,000. Summit Securities Group LLC bought a new stake in shares of Spyre Therapeutics in the first quarter valued at about $28,000. Royal Bank of Canada boosted its position in shares of Spyre Therapeutics by 63.5% in the first quarter. Royal Bank of Canada now owns 3,250 shares of the company’s stock valued at $164,000 after acquiring an additional 1,262 shares during the period. Finally, KBC Group NV acquired a new position in shares of Spyre Therapeutics in the first quarter valued at about $69,000. 80.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SYRE. Guggenheim lifted their price objective on shares of Spyre Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Mizuho upped their target price on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spyre Therapeutics in a research note on Tuesday, September 1st. Wells Fargo & Company lifted their price target on Spyre Therapeutics from $90.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Finally, Wolfe Research downgraded Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $109.71.

Read Our Latest Stock Analysis on Spyre Therapeutics

Key Stories Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

Positive Sentiment: Analyst support strengthened: BTIG Research reaffirmed its “buy” rating and assigned a $121 price target, while JPMorgan initiated coverage with an “overweight” rating and a $110 target. The recommendations imply meaningful potential upside from recent trading levels and provide positive validation for Spyre’s immunology pipeline. BTIG Research rating report
Neutral Sentiment: Employee inducement awards announced: Spyre granted two new employees options covering 21,424 shares and 6,604 restricted stock units. The awards were required to support hiring and are not directly related to clinical or financial results, although they could modestly increase future share dilution. Spyre Therapeutics inducement awards announcement
Negative Sentiment: Multiple insiders sold shares: CEO Cameron Turtle sold 15,000 shares, CFO Scott Burrows sold a combined 25,000 shares, and insider Heidy King-Jones sold 28,933 shares. The transactions represent notable reductions in ownership, particularly King-Jones’s roughly 91% decrease, which may raise caution about insider sentiment. However, all sales were executed under pre-arranged Rule 10b5-1 trading plans, reducing their significance as discretionary signals of declining confidence. Spyre insider trading filing

Spyre Therapeutics Company Profile

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions.